– New office in Mexico to help address the growing demand for pain management in Latin America’s second largest market
– Over 28 million people are estimated to suffer from chronic pain in Mexico with few analgesic alternatives
– The company will also enter the oncology arena with a new treatment recently approved by the Comision Federal para la Proteccion contra Riesgos Sanitarios (COFEPRIS), the Mexican federal health authority
SINGAPORE, Sept. 11, 2014 /PRNewswire/ — Mundipharma has announced the opening of its new office in Mexico. The company intends to focus its global leadership in pain management on meeting the analgesic and oncological treatment needs of the market.
Based in Mexico City, Mundipharma’s expansion into Latin America’s second largest economy is the latest development in its plans to better improve the quality of lives for sufferers of chronic pain in the region. The company last year announced the opening of offices in Brazil and Colombia in November 2013.
"We are very excited to start formal activities in Mexico and bring Mundipharma’s valuable expertise in pain relief to the over 28 million people estimated to suffer from chronic pain in the country today," said Raman Singh, President of Mundipharma Asia-Pacific, Latin America, the Middle East and North Africa.
As the economies of Latin American countries continue to evolve, chronic and non-communicable diseases such as cancer and diabetes have become the leading cause of illness in the region. To address this issue, Mundipharma’s operations in Mexico begin with a focus on analgesia and oncology. The company plans to introduce several products to treat chronic pain and cancer, each proven to encompass an outstanding degree of effectiveness, reliability and safety. In addition, a new oncology treatment recently approved by the COFEPRIS is already in the pipeline.
Raman Singh stated "Mundipharma is a leader in the science of pain, and we are widely recognized worldwide for medical innovations in this area. Here in Mexico we are eager to start designing and contributing a portfolio of reliable and high-quality analgesic products to relieve the pain suffered by millions of people and their families."
Mundipharma’s global network of companies are privately owned entities covering the world’s pharmaceutical markets. Mundipharma provides patients across 5 continents with a growing portfolio of products in 5 therapeutic areas, which include moderate-to-severe pain, consumer healthcare, oncology, respiratory disease, rheumatoid arthritis, antisepsis and laxatives. Mundipharma is a prime example of a company that consistently delivers high quality products while standing by the values that represent the company. Our mission is to alleviate the suffering of patients with cancer and non-cancer pain and to substantially improve their quality of life.
For more information please visit: http://www.mundipharma.com.sg
Regional Communications & Corporate Marketing Director
Asia Pacific, Latin America, Middle East and Africa, Mundipharma
Dr. Covarrubias-Gomez, Alfredo Et Al. Anestiologia, Vol 3, No. 4, Octubre — Diciembre 2010, Epidemiologia del dolor cronico en Mexico, p. 208. Last accessed on 26 Aug 2014
Inter Development American-Bank, Many hospitalizations due to chronic disease preventable, IDB study hows, 16 Dec 2011. Last accessed on 25 Aug 2014.